Details

Autor(en) / Beteiligte

• Bando, Yukari
• Furukawa, Junya
• Okamura, Yasuyoshi
• Hara, Takuto
• Terakawa, Tomoaki
• Nakano, Yuzo
• Fujisawa, Masato

Titel

Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma

Ist Teil von

• Anticancer research, 2022-02, Vol.42 (2), p.973-979

Ort / Verlag

Greece: International Institute of Anticancer Research

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively. We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups. Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04). Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.